Sign up Australia
Proactive Investors - Run By Investors For Investors

Cyclopharm eyes faster market entry for Technegas following positive US FDA meeting

Technegas is inhaled by patients and allows the diagnosis of multiple respiratory diseases via imaging and analytical software
lungs
Commercial sales expected to commence in the US during 2019

Cyclopharm Limited (ASX:CYC) has opened up an alternative pathway for the approval of its Technegas generator following a meeting with the United States Food and Drug Administration (US FDA).

The Technegas generator produces a gas which is inhaled by patients before taking scans, to assist in the detection of respiratory diseases.

The newly proposed pathway is likely to allow for a faster market entry and reduced risk profile.

As a result, Cyclopharm is likely to be in a position to submit its New Drug Application for Technegas during the first half of 2019.

READ: Cyclopharm achieves another milestone for its Technegas technology in the US

Cyclopharm managing director James McBrayer said: “Being allowed to submit a New Drug Application protocol for Technegas via a 505 (b)2 pathway significantly de-risks the FDA approval process, gives confidence to our timeline target to start sales of Technegas in the US in 2019 and is likely to reduce the anticipated overall costs (USD $7.5 million) of gaining approval USFDA substantially.

“We will redeploy any savings we make from adopting this alternative approval pathway to building the distribution, sales and marketing capabilities needed to initiate US sales in 2019.”

Aiming for 50% share of the US market

The US accounts for around half of the total addressable global market for Technegas.

The existing market for nuclear medicine ventilation imaging in the US is estimated to be about US$90 million annually, representing 600,000 individual procedures

Based on its Canadian experience, Cyclopharm believes that Technegas can achieve a 50% share of the US market over 2 to 3 years, post-market entry, with an 80% share representing about 480,000 procedures per annum achievable over a 7-year period.

View full CYC profile View Profile

Cyclopharm Ltd Timeline

Related Articles

1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use